Velmanase alfa
Velmanase alfa (LAMZEDE) is an enzyme replacement therapy used to treat the physical symptoms of alpha-mannosidosis, a rare inherited storage disease.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
LAMZEDE can cause severe allergic reactions, including anaphylaxis — a sudden, life-threatening reaction that can affect breathing and blood pressure. This risk applies to any patient treated with this medicine. Every infusion must take place where emergency equipment (including CPR equipment) is immediately available. Watch for warning signs during or after the infusion, such as hives, swelling, vomiting, a drop in blood pressure, or bluish skin. If a severe reaction happens, the infusion must be stopped at once and emergency medical treatment started immediately.
📖 Velmanase alfa: Patient Information Guide
A plain-language walkthrough of Velmanase alfa — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Velmanase alfa (LAMZEDE) is approved to treat the physical — non-brain-related — symptoms of alpha-mannosidosis in adults and children. This is a rare inherited condition where the body cannot properly break down certain sugar-containing molecules.
- Treatment of non-central nervous system (non-CNS) manifestations of alpha-mannosidosis
- Approved for both adult and pediatric patients
⚙️How it works▾
Alpha-mannosidosis is caused by a genetic change that leaves the body with little or no working alpha-mannosidase enzyme. This enzyme is responsible for breaking down sugar-containing waste products inside lysosomes — tiny compartments inside cells that act like recycling centers. Without it, waste accumulates and damages tissues throughout the body.
Velmanase alfa supplies a working copy of this missing enzyme. After infusion into the bloodstream, it binds to a receptor on the cell surface called the mannose-6-phosphate receptor, which carries it into the lysosome. Inside the lysosome, it is thought to break down the accumulated waste, reducing its harmful buildup.
💊How it's taken▾
Velmanase alfa is given as an intravenous (IV) infusion once every week at a clinic or infusion center — it cannot be taken by mouth. Each infusion lasts at least 60 minutes; the exact rate may be adjusted based on weight or how you are tolerating the infusion.
- Before each infusion, your care team may pre-treat you with antihistamines, fever reducers, or corticosteroids to reduce the chance of a reaction
- If you miss a dose, restart as soon as possible — unless your next scheduled dose is within 3 days, in which case just take the next scheduled dose as planned
- Always follow your care team's specific instructions
🤒Side effects — in detail▾
The most commonly reported side effects in clinical trials included:
- Nasopharyngitis (cold-like symptoms)
- Fever
- Headache
- Joint pain (arthralgia)
- Hypersensitivity (allergic) reactions
- Tonsillitis
- Eye itching
- Fainting (syncope)
- Gastroenteritis (stomach upset with nausea or diarrhea)
More seriously, some patients have experienced anaphylaxis or severe allergic infusion reactions, and one patient developed acute kidney failure. Tell your care team immediately if you feel unwell during or after an infusion.
⚠️Warnings & precautions▾
- Severe allergic reactions and anaphylaxis: Half of all patients in trials had some form of allergic reaction. Five percent experienced anaphylaxis. Emergency equipment must be available at every infusion. Signs include hives, facial swelling, vomiting, low blood pressure, bluish skin, or tremor.
- Infusion-associated reactions (IARs): Reactions tied to the infusion itself can occur. Mild reactions may be managed by slowing or pausing the infusion; severe reactions require stopping the infusion and emergency treatment.
- Embryo-fetal toxicity: Animal studies showed serious birth defects at exposures relevant to human dosing. Women who could become pregnant must use effective contraception during treatment and for 14 days after stopping.
- Antibody development: Some patients developed anti-drug antibodies (ADA), which were associated with more severe allergic reactions.
🔀What it interacts with▾
The FDA label for velmanase alfa does not identify specific drug, food, or supplement interactions.
- Always tell your full care team about every medication, supplement, and herbal product you take before starting velmanase alfa
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Pregnancy: This medicine may cause serious harm to an unborn baby. Women who could become pregnant must be confirmed not pregnant before starting and must use effective contraception during treatment and for 14 days after the last dose.
- Previous severe allergic reactions: If you have had anaphylaxis or a severe reaction to velmanase alfa before, discuss with your doctor whether it is safe to continue — a desensitization procedure may be considered.
- Children: Velmanase alfa has been studied in children as young as 3 years old. Dosing is based on body weight; your care team will manage this carefully.
- Anti-drug antibodies: Patients who develop antibodies against this medicine appear to be at higher risk for serious allergic reactions — your care team may monitor for this.
📡Pharmacodynamics — effects in the body▾
In people with alpha-mannosidosis, the blood contains high levels of sugar-containing waste molecules called oligosaccharides. These elevated levels serve as a measurable marker of how active the disease is. In clinical studies, treatment with velmanase alfa led to meaningful reductions in these serum oligosaccharide levels, suggesting the enzyme is successfully breaking down the accumulated waste in the body.
🔬Pharmacokinetics — how your body processes it▾
Velmanase alfa reaches its peak blood concentration during the weekly IV infusion, then is gradually cleared from the body. Its mean terminal half-life — the time it takes for half the drug to leave the body — is about 33.6 hours in adults. The drug is broken down through normal protein-digesting pathways into small peptides (protein fragments). In children aged 6–17, the drug behaves similarly to adults at the same weight-based dose, though blood levels are somewhat lower than in adults.
📦How to store it▾
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
📄 Written from Velmanase alfa’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Velmanase alfa — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is alpha-mannosidosis, and how does this medicine help? ▾
How is this medicine given, and will I need to go somewhere special for it? ▾
What side effects should I expect, and which ones are a reason to call for help? ▾
I'm a woman of childbearing age. Is there anything I need to know before starting this? ▾
What happens if I miss a weekly dose? ▾
I heard that some people develop antibodies to this medicine. What does that mean for me? ▾
Is Velmanase alfa available over the counter? ▾
💬 Answers drafted from Velmanase alfa’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
📈 How widely Velmanase alfa is used
A general measure of how commonly Velmanase alfa is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Velmanase alfa is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Velmanase alfa prescribed? Of the 1,596 medications we measure, Velmanase alfa ranks #1,496 by Medicaid prescriptions — more than 6% of them.
Utilization by Velmanase alfa product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
velmanase alfa-tycv 10 MG Injection
Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2630729
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Velmanase alfa, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 4 listed Velmanase alfa NDCs with Medicaid activity.
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Velmanase alfa — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Velmanase alfa in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Velmanase alfa went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2630725 1 dose form · 1 strength
-
Dose form (SCDF) Injection RxCUI 2630728No current FDA listingClinical drug / strength (SCD) tycv 10 MGRxCUI 2630729
Look up RxCUI 2630725 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Velmanase alfa is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
RxNorm drug class
Velmanase alfa belongs to the Recombinant Human Lysosomal alpha-Mannosidase class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Chiesi USA, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.